Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 9Paclitaxel 9Doxorubicin 6Cyclophosphamide 6Carboplatin 5130-nm albumin-bound paclitaxel 5durvalumab 3yeast-CEA vaccine 2talazoparib 2sacituzumab govitecan 2olaparib 2glembatumumab vedotin 2avelumab 2Taxes 2Radiotherapy 2Leucovorin 2Fluorouracil 2Cisplatin 2Capecitabine 2Biopsy 2Albumin-Bound Paclitaxel 2ALT-803 2zimberelimab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab duocarmazine 1tislelizumab 1taxane 1sabizabulin 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Triple Negative Breast Neoplasms × Omacor × Clear all
NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡